News

Bavarian Nordic's JYNNEOS available to healthcare providers nationwide.

The case was confirmed in Texas and the person was in contact with cows. CDC says the risk for infection remains low.

April marks STI Awareness Month; guidelines decreasing the incidence of chlamydia and syphilis, future work needing to be done with regards to doxy-PEP, an increase in STIs during the pandemic, and more from this year by Contagion.

This very large study reviewed data, which showed people vaccinated for the virus had a substantial reduction of risk for these types of events.

Rising dengue incidence in Puerto Rico signals broadening health concerns.

Clinicians review a patient case including diagnosis, treatment, and follow-up.

A study on the impact of guidelines on reducing hospital-onset CDI incidence.

Clinicians discuss screening and treatment approaches for the disease.

FDA authorizes Ito Invivyd’s pemivibart (Pemgarda), insights on Sofosbuvir levels in pregnant women, the effectiveness of fidaxomicin vs vancomycin for CDI treatment, and more this week from Contagion.

A surge in meningococcal disease cases linked to Serogroup Y.

The company's latest investigational vaccine induced a greater immune response compared to its FDA approved Spikevax product.

Impact of the RSVPreF3 vaccine on respiratory illness in older adults in the US.

Atea Pharmaceuticals bemnifosbuvir aims to help high-risk COVID-19 patients with a new oral option.

A study conducted in China aimed to assess factors such as viral load rebound (VLR), reduction in cycle threshold values, time until VLR, and symptom rebound.

Phase 2 study of healthcare workers' safety in high-risk populations.

In today’s world of sophisticated, complex tests, an evolving relationship between laboratory professionals and clinicians can aid in providing a quicker diagnosis and help to achieve better patient outcomes.

The potential of enzyme cocktails for enhanced mycobacterial infection management.

There is value in leveraging the contributions of nurses, laboratorians, and informaticists in antimicrobial stewardship.

Latest discoveries around HpaA's implications for immune response and disease progression.

The assay, the cobas Malaria test, is manufactured by Roche, and will be available in the United States at the end of Q2 2024.

Insights from a CDC study on challenges and research direction in pediatric hepatitis.

The increase highlights the threat posed by climate change and the need for innovative preparedness, prevention, and mitigation tools.

Bulevirtide's key role in blocking hepatitis virus entry.

The role of the US President’s Emergency Plan for AIDS Relief in combating tuberculosis (TB).

The long-term benefits of antimicrobial use and resistance (AUR) reporting is about improving patient care and combating resistance.

Insights on Sofosbuvir levels in pregnant women.

A new strategy for universal infant immunization in the 2023-2024 RSV season faces implementation and medication access barriers.

The evolution of treatment for hepatitis C virus during the past 15 years has been astounding, and we now are able to talk about how HCV could be eliminated.

The authorization was given to Invivyd’s pemivibart (Pemgarda), and it is indicated for adults and adolescents with moderate-to-severe immune compromised conditions.

Here is a review of the effectiveness of fidaxomicin vs vancomycin for CDI treatment in populations with immunocompromised conditions.